Printer Friendly

Research and Markets: Bacillus Anthracis Infections - Pipeline Review, H2 2012.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/7c6nhf/bacillus) has announced the addition of Global Markets Direct's new report "Bacillus Anthracis Infections - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Bacillus Anthracis Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacillus Anthracis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacillus Anthracis Infections.

Scope

- A snapshot of the global therapeutic scenario for Bacillus Anthracis Infections.

- A review of the Bacillus Anthracis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Bacillus Anthracis Infections pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bacillus Anthracis Infections.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Bacillus Anthracis Infections pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit

http://www.researchandmarkets.com/research/7c6nhf/bacillus

Source: Global Markets Direct
COPYRIGHT 2013 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 4, 2013
Words:376
Previous Article:In CES Presentation, Consumer Electronics Association and GfK Will Reveal Consumer Preferences among Emerging Car Technologies.
Next Article:National Penn Bancshares, Inc. to Release 4th Quarter and Full Year 2012 Earnings, Conduct Webcast Conference Call on Thursday, January 24, 2013.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters